Grantham, Mayo, Van Otterloo & Co (GMO)’s Axcelis ACLS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACLS
RP
Grantham, Mayo, Van Otterloo & Co (GMO)'s ACLS Position: Q2 2026 in Review
Grantham, Mayo, Van Otterloo & Co (GMO) reduced its Axcelis (ACLS) stake by 60% in Q2 2026, selling an estimated $29.6M and leaving 135,580 shares worth $25.7M. The position accounts for 0.06% of the portfolio, ranked #153.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ACLS in Q2 2019 and has held it in 24 quarters since. The position peaked at $53.4M in Q4 2024. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) held 135,580 shares of Axcelis worth $25.7M as of Q2 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) sold 199,206 Axcelis shares in Q2 2026, an estimated $29.6M.
- Axcelis made up 0.06% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q2 2026, its #153 holding.
- Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Axcelis in Q2 2019 and has held it in 24 quarters since.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s Axcelis position peaked at $53.4M in Q4 2024.
- 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.
Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.